Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401386 | 0.91 | TACR1 (0.48) | TACR1ALDH1A1TDP1HTR2CHTR2B | |
| SCHEMBL5384916 | 0.84 | TACR1 (0.59) | TACR1HTR2CHTR2BHTR7 | |
| SCHEMBL6651268 | 0.84 | TACR1 (0.51) | TACR1HTR2CHTR2BHTR7CDK9 | |
| SCHEMBL5388810 | 0.83 | ALDH1A1 (0.42) | TACR1ALDH1A1TDP1MAPTPKM | |
| SCHEMBL5400718 | 0.81 | TACR1 (0.50) | TACR1HTR2CHTR2BHTR7MAPT | |
| SCHEMBL5400714 | 0.81 | TACR1 (0.50) | TACR1HTR2CHTR2BHTR7MAPT | |
| SCHEMBL5390197 | 0.80 | ALDH1A1 (0.41) | TACR1ALDH1A1TDP1HTR2CHTR2B | |
| SCHEMBL3339129 | 0.80 | ALDH1A1 (0.42) | TACR1ALDH1A1TDP1HTR7MAPT | |
| SCHEMBL8944811 | 0.76 | MAPT (0.49) | ALDH1A1MAPTPKM | |
| SCHEMBL5390992 | 0.75 | MAPT (0.44) | ALDH1A1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1423117-B1 | 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | TACR1 49/4885ALDH1A1 1543/4885TDP1 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.